MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. PBH
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Prestige Consumer Healthcare In (PBH) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Prestige Consumer Healthcare In
NYSE•Healthcare•Drug Manufacturers - Specialty & Generic
$46.62-0.24(-0.01%)Market open
Market Cap
$2.13B
P/E
12.4x
P/S
1.9x
P/B
1.1x

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

C

How this company scores

AverageMetricSide Score: 44/100

Strongest: Cash & Earnings Quality (18/25); weakest: Growth (5/25).

Profitability12/25
Growth5/25
Balance Sheet & Red Flags9/25
Cash & Earnings Quality18/25
Strengths
Strong marginsCash-backed earningsConsistent free cash flowNo share dilution

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 12.4x5y range 12.0x – 19.9x
P/E 12.4x · near its 16-quarter median

Currently near its 16-quarter median.

P/S · 1.9x5y range 1.9x – 3.8x
P/S 1.9x · below its 20-quarter median

Currently below its 20-quarter median.

P/B · 1.1x5y range 1.1x – 2.3x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Margin Pressure

Watch

Operating margins declined 12.7% — watch for continued compression, which may signal competitive or cost pressure.

Leverage Risk

Watch

Debt-to-equity has risen 95.7% recently — increasing financial risk even if the current ratio is manageable.

Price & Volume
Market Cap $2.13B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$1.10B
1%
Q. Revenue
$265.71M
2Q
TTM EBITDA
$337.79M
5Q
TTM Op. Income
$290.17M
5Q
Q. Op. Income
$52.52M
2Q
TTM Net Income
$172.01M
19%
Q. Net Income
$29.18M
39%
EPS
$0.61
36%
Shares Out.
$47.46M
4%
$1.10B in TTM revenue declined 1.4% YoY, reaching $265.71M last quarter. TTM EBITDA of $337.79M and TTM operating income of $290.17M show growth is flowing through to the bottom line. TTM net income of $172.01M means revenue is converting into profit. Over the past year, TTM revenue is down 1% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
51.3%
2Q
EBITDA Margin
23.1%
28%
Op. Margin
19.8%
2Q
Net Margin
11.0%
42%
Op. margin of 19.8% is down 9.0% YoY — costs are rising relative to revenue. Net margin at 11.0% and gross margin of 51.3% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
12.4x
2Q
P/S Ratio
1.9x
5Q
P/B Ratio
1.1x
5Q
At 12.4x P/E, the stock trades below typical market levels. P/S of 1.9x and P/B of 1.1x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has fallen for 2 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$4.57B
33%
Cash
$89.13M
2Q
Long-Term Debt
$2.01B
102%
Book Value
$1.92B
3Q
D/E Ratio
1.0
96%
Debt/EBITDA
32.8
162%
With $4.57B in assets and $2.01B in long-term debt, D/E is 1.0and book value is $1.92B — moderate leverage. Over the past year, debt/equity is up 96% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$70.79M
10%
TTM Free Cash Flow
$235.36M
2Q
FCF Margin
21.3%
2Q
FCF / Net Income
1.4
9%
TTM FCF of $235.36M on $70.79M in operating cash flow. The FCF / Net Income ratio of 1.4x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
P/B 1.1x
· below its 20-quarter median

Currently below its 20-quarter median.

Revenue Decline

Watch

Revenue has softened, declining in 4 quarters. Watch for further erosion.